Bristol Myers Squibb
Search results
Learn how Celgene, a global biopharmaceutical company, is committed to improving the lives of patients worldwide by delivering truly innovative and life-changing treatments. Explore the therapies for Hematology, Oncology, Inflammation and Immunology and the medical research to help people live longer, better, and healthier.
Footnotes / references. [1] Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid ( lenalidomide ), which is used in the treatment of multiple myeloma, and also in certain anemias.
Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders.
Learn about the Risk Evaluation and Mitigation Strategy (REMS) programs for THALOMID, POMALYST and REVLIMID, which are administered by Bristol Myers Squibb. Find out how to enroll, comply and access the REMS programs as a prescriber, patient or pharmacy.
Jan 3, 2019 · Copies of the documents filed with the SEC by Celgene will be available free of charge on Celgene’s internet website at https://www.celgene.com/ under the tab “Investors” and under the heading “Financial Information” and subheading “SEC Filings” or by contacting Celgene’s Investor Relations Department at ir@celgene.com.
BMS is a leading biopharmaceutical company that develops and delivers innovative medicines for serious diseases. Learn about its latest cell therapy milestone, its ESG report, its careers, and its clinical trial and medical information resources.
Nov 20, 2019 · Bristol-Myers Squibb Co. has closed its deal to buy Celgene Corp., one of the largest in pharmaceutical history. The merger combines nine products with more than $1 billion in annual sales and creates a leading biopharma company.
